Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study

Philip H. Keiser, Naiel Nassar

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

A retrospective electronic database study was conducted to determine any differences in time to virological failure and percent of virological failure among HIV-infected patients concurrently receiving H2-blockers versus patients not receiving these agents while receiving atazanavir (ATV)/ritonavir (r) or lopinavir (LPV)/r-containing antiretroviral treatment regimens. Data were culled from October 2003 (when ATV became commercially available) through February 2006. Virological failure was defined as (1) two plasma HIV-1 RNA levels >400 copies/mL after at least one HIV-1 RNA level below the level of detection or (2) failure to achieve an HIV-1 RNA <400 copies/mL within 24 weeks. Data from 267 ATV/r-treated patients who met the case definition were compared with data from 670 LPV/r-treated patients. Approximately 10% of the ATV/r group received concurrent H2-blockers when compared with 20% of the LPV/r group. Multivariate analysis showed no statistically significant differences regarding time to virological failure between or among the four subgroups, adjusting for differences in baseline characteristics (P = 0.79, log-rank test). At 750 days following treatment initiation, the proportion of patients not experiencing virological failure was 56% in the ATV/r-blocker subgroup, 48% in the ATV/r-alone subgroup, 45% in the LPV/r-alone subgroup and 42% in the LPV/r-blocker subgroup.

Original languageEnglish (US)
Pages (from-to)561-562
Number of pages2
JournalInternational Journal of STD and AIDS
Volume19
Issue number8
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

Keywords

  • Acid-reducing agents
  • Atazanavir
  • Complications
  • Drug interactions
  • H-blockers
  • Kaletra
  • Virologic failure

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H<sub>2</sub>-receptor blocker, not significantly different in HIV observational database study'. Together they form a unique fingerprint.

  • Cite this